Identifying biomarkers associated with Alzheimer's disease (AD) progression may enable patient enrichment and improve clinical trial designs. 4 key findings →
Participants: 19
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Cigarette smoking is associated with increased risk for myriad health consequences including cognitive decline and dementia, but research on the link between smoking and brain structure is nascent. 4 key findings →
Participants: 19,615
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a large multi-center study designed to develop optimized methods for acquiring longitudinal neuroimaging, cognitive, and biomarker measures of AD progression in a large cohort of patients with Alzheimer's disease (AD), patients with Mild Cognitive Impairment, and healthy controls. 4 key findings →
Design: longitudinal study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
51/100
✓ Peer-reviewed
alzhub usefulness score 51 out of 100.
·
Aging cell
·
2021-08-07
While insulin-like growth factor-1 (IGF-1) is a well-established modulator of aging and longevity in model organisms, its role in humans has been controversial. 4 key findings →
Participants: 440,185
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
The association of testosterone concentrations with dementia risk remains uncertain. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
The present study investigated the ability of the Multilingual Naming Test (MINT), a picture naming test recently added to the National Alzheimer's Coordinating Center's (NACC) Uniform Data Set neuropsychological test battery, to detect naming impairment (i.e., dysnomia) across stages of Alzheimer's disease (AD). 4 key findings →
Design: cross-sectional
Participants: 3,981
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
Visinin-like protein-1 (VILIP-1) and chitinase-3-like protein 1 (CHI3L1 or YKL-40) in cerebrospinal fluid (CSF) are newly discovered markers indicating neuronal damage and microglial activation, respectively. 4 key findings →
Participants: 121
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
51/100
✓ Peer-reviewed
alzhub usefulness score 51 out of 100.
·
Stroke
·
2016-07-14
Improved short-term survival after stroke has necessitated quantifying risk and risk factors of long-term sequelae after stroke (ie, recurrent stroke and dementia). 4 key findings →
Participants: 1,237
Evidence: low
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
Plasma amyloid-β (Aβ) levels are increasingly studied as a potential accessible marker of cognitive impairment and dementia. 4 key findings →
Participants: 458
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
Alzheimer's disease (AD) is the leading cause of dementia, characterized by the accumulation of amyloid-beta (Aβ) and neurofibrillary tangles. 4 key findings →
Participants: 16
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
51/100
✓ Peer-reviewed
alzhub usefulness score 51 out of 100.
·
PloS one
·
2019-10-04
In recent years, several high-dimensional, accurate, and effective classification methods have been proposed for the automatic discrimination of the subject between Alzheimer's disease (AD) or its prodromal phase {i.e., mild cognitive impairment (MCI)} and healthy control (HC) persons based on T1-weighted structural magnetic resonance imaging (sMRI). 4 key findings →
Participants: 326
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
White matter hyperintensities (WMH) are among the most common radiological abnormalities in the ageing population and an established risk factor for stroke and dementia. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
Functional decline is associated with risk and can be efficiently assessed by participants and study partners (SPs). 4 key findings →
Design: longitudinal study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
51/100
✓ Peer-reviewed
alzhub usefulness score 51 out of 100.
·
GeroScience
·
2025-06-30
Higher AD PRS was associated with increased risks of all-cause dementia (HR: 1.75, 95% CI: 1.70-1.79, P < 0.001) and AD (HR: 2.02, 95% CI: 1.95-2.09, P < 0.001), with stronger effects in women for both outcomes when considering the main AD PRS which was related to APOE4 status. 4 key findings →
Participants: 249
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
A total of 43,160 participants were included (mean [standard deviation] age, 64.2 [7.7] years, 53.1 % female). 5 key findings →
Design: cross-sectional
Participants: 43,160
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
MASLD was significantly associated with smaller volumes of total grey matter and subcortical grey matter (p < 0.05) and reduced Alzheimer's disease (AD)-signature cortical thickness (multivariable-adjusted β = -0.04; 95% confidence interval [CI]: -0.07, -0.01). 4 key findings →
Design: cross-sectional
Participants: 29,195
Evidence: low
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
We identified all participants in the UK Biobank cohort study diagnosed with HF prior to enrolment or during follow-up, who had disease occurrence data available from both primary and secondary care records (n = 9824). 5 key findings →
Design: cohort study
Participants: 9,824
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Shorter LTL was associated with an increased risk of NDDs, including Alzheimer's disease (HR: 0.52, 95% CI 0.40-0.67, P < 0.001), dementia in AD (HR: 0.53, 95% CI 0.39-0.73, P < 0.001), unspecified dementia (HR: 0.74, 95% CI 0.58-0.95, P < 0.05), degenerative diseases of the nervous system (including other specified degenerative diseases such as circumscribed brain atrophy and senile degeneration of the brain) (HR: 0.62, 95% CI 0.45-0.84, P < 0.01), extrapyramidal and movement disorders (including other specified extrapyramidal and movement disorders such as a range of tremors, chorea, tics, and other abnormal involuntary movements) (HR: 0.63, 95% CI 0.48-0.82, P < 0.01), and mental and behavioral disorders due to use of alcohol (HR: 0.46, 95% CI 0.38-0.55, P < 0.001). 5 key findings →
Participants: 459,902
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Our findings highlight the altered phases of swallowing in patients with dementia. 4 key findings →
Design: cross-sectional
Participants: 158
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
A Clinical Task Force, composed of clinical leaders from Alzheimer's Disease Centers (ADC), was convened by the National Institute on Aging to develop a uniform set of assessment procedures to characterize individuals with mild Alzheimer disease and mild cognitive impairment in comparison with nondemented aging.
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
The Cardiovascular Health Study is a population-based, longitudinal study designed to evaluate factors related to the onset, course, and risk of coronary heart disease and stroke in adults aged 65 years and older. 4 key findings →
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
The Rotterdam Study is a prospective cohort study ongoing since 1990 in the city of Rotterdam in The Netherlands.
Full summary, score breakdown and related studies →
Original source
Free full text
50/100
✓ Peer-reviewed
alzhub usefulness score 50 out of 100.
·
Stroke
·
1994-06-01
Ventricular enlargement and white matter lesions are frequent findings on cerebral magnetic resonance imaging scans of elderly subjects. 4 key findings →
Participants: 90
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
In this article, the authors aim to maximally utilize multimodality neuroimaging and genetic data for identifying Alzheimer's disease (AD) and its prodromal status, Mild Cognitive Impairment (MCI), from normal aging subjects. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
Glymphatic dysfunction is a crucial pathway for dementia. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor,
and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a
scientist can tell a landmark trial from a conference abstract without having to already know the
difference. Every point comes from one of 20 components, all of them printed on the study itself,
so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we
could not verify current impact factors from a source we control, and an invented one would be
worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science,
Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed
journal. A separate part scores how much the journal's own papers are cited, which tells the
tier-3 journals apart.
Two rules we don't bend. First, we never fill in a
missing value: if a record does not state a sample size or a design, that component scores
zero, and if we simply have no data for a part, such as a citation count, that part is left out and
the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed
article is capped at 16/100 and carries a warning chip — so a conference abstract or
a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not
work — above an early positive finding. Someone deciding whether to buy a supplement is served by
that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is
reproducible: the same file always yields the same numbers.
See the whole rubric drawn out →
— four charts covering all 27,380 studies: how the scores are spread and where the cap
bites, which of the 20 components the library is strong and weak on, which subjects rest on
stronger evidence, and what kinds of study each subject is actually built from.